Best Hospitals for Uterine Cancer Treatment in UAE

Uterine cancer — the most common gynecologic malignancy in developed nations — arises predominantly from the endometrial lining (endometrial carcinoma, ~90% of cases) or, less commonly, from the uterine musculature (uterine sarcoma, including leiomyosarcoma and carcinosarcoma). Endometrial carcinoma is histologically classified into Type I (estrogen-driven, endometrioid adenocarcinoma, typically low-grade and confined to the uterus at diagnosis) and Type II (non-estrogen-driven, including serous, clear cell, and undifferentiated carcinomas, which carry a more aggressive biological course). Molecular subtyping per The Cancer Genome Atlas (TCGA) framework — POLE ultra-mutated, mismatch repair deficient (MMRd/MSI-H), copy-number low, and copy-number high (p53-mutant serous-like) — now directly informs adjuvant therapy decisions and immunotherapy eligibility.

• ELIGIBLE PATIENTS:
• Postmenopausal women with confirmed endometrial biopsy or hysteroscopic biopsy showing endometrial carcinoma or uterine sarcoma at any FIGO stage
• Premenopausal women with histologically confirmed diagnosis who are not candidates for fertility-sparing management
• Patients with FIGO Stage IA Grade 1–2 endometrioid carcinoma seeking fertility-sparing hormonal therapy (high-dose progestins + levonorgestrel IUD) — strictly under specialist guidance and with mandatory follow-up biopsies
• Patients with recurrent or metastatic disease requiring systemic therapy (chemotherapy, targeted therapy, or immunotherapy)
• +18 more

Surgical APPROACHES:

1. Robotic-Assisted Laparoscopic Hysterectomy (da Vinci Si/Xi System): The preferred modality for most Stage I–II cases at high-volume cancer centres. Offers 3D magnification, wristed instrument precision, and superior access in the deep pelvis — critical for obese patients (BMI >35) who comprise a disproportionate share of endometrial cancer cases. Paired with ICG-based sentinel lymph node mapping (RELSN procedure), robotic surgery achieves equivalent oncologic clearance to open surgery with significantly shorter hospitalization (2–3 days), faster return to activity, and lower blood loss (<100 mL average).

2. Total Laparoscopic Hysterectomy (TLH) with BSO and SLN Biopsy: A cost-effective minimally invasive alternative to robotic surgery; widely performed at India's top oncology centres. Uses ICG fluorescence or technetium-99m radiocolloid ± blue dye for sentinel node identification. Avoids the morbidity of complete systematic pelvic lymphadenectomy in appropriately selected patients.

3. Open (Laparotomy) Radical Hysterectomy: Reserved for Stage III disease with parametrial/bladder/bowel involvement, large uterine sarcomas, or cases requiring en bloc resection of adjacent structures. Wertheim's radical hysterectomy (Type III) with pelvic and para-aortic lymphadenectomy is the benchmark for locally advanced disease.

PHASE 1 — PRE-ARRIVAL & VIRTUAL CONSULTATION (Week 1–2 before travel):

• Submit medical records, biopsy reports, imaging (MRI/PET-CT), and pathology slides to GAF Healthcare's assigned gynecologic oncologist via secure online portal.
• Receive a detailed multidisciplinary tumor board (MDT) opinion within 48–72 hours, including recommended surgical approach, molecular testing requirements, and estimated treatment timeline.
• GAF Healthcare initiates e-Medical Visa application (India) or coordinates tourist/medical entry visa (UAE) based on patient nationality.
• Pre-operative blood work, cardiac clearance, and anaesthesia assessment forms are sent to local physician for preliminary completion.

PHASE 2 — ARRIVAL & PRE-OPERATIVE WORKUP (Days 1–3 in destination):